SGCB and endothelial dysfunction: After having demonstrated that runcaciguat can reduce proteinuria in a rat model of hypertension and proteinuria (ANG-SD rats), we investigated its potential cardiovascular and cardio-renal benefits in a more disease-relevant rat model with low nitric oxide (NO) bioavailability, interruption of the NO-sGC signaling, endothelial dysfunction, and hypertension.